Design thinking and design doing: Describing a process of people-centred innovation

The research forms part of the author’s long-term enquiry into the challenges of implementing Design Thinking (DT) and its relationship to Inclusive Design (ID), something that has been understudied and under-researched. Both fields advocate research with users and have a history spanning decades, but they have remained largely separate in terms of academic research and practical application. The author was approached by the series editor for his expertise at the intersection of ID and DT. “State of the art” DT ideas and approaches were evaluated through study of circa 50 recent academic publications, papers and journal articles. Field research was based on personal leadership of over 70 ID projects with government, business, and the voluntary sector leading to frontline discoveries and insights. Peer-reviewed academic publication, conference presentation, and keynote delivery helped test ideas before making the link between ID and DT and delivering the publication. This 13,000 word, sole-authored chapter outlines gaps in the long-term effectiveness of DT, outlining five principles that aim to engender a more sustainable approach by aligning it to ID. These five ideas give an overview of newly-articulated frameworks, tools and methods for academic and industry application. The chapter sets a context for 16 other chapters within the publication and establishes the need for more empirical research to link between DT and ID. The ideas in the chapter have been used to direct practice-based research projects and education programmes at the RCA as well as organisations in its network. 700 Hong Kong civil servants have been trained using these ideas, alongside numerous industry organisations including Tata Consulting Services and Panasonic

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)